Disc Medicine Future Growth
Future criteria checks 0/6
Disc Medicine is forecast to grow earnings and revenue by 20.4% and 64.1% per annum respectively. EPS is expected to grow by 23.2% per annum. Return on equity is forecast to be -101.5% in 3 years.
Key information
20.4%
Earnings growth rate
23.2%
EPS growth rate
| Biotechs earnings growth | 27.2% |
| Revenue growth rate | 64.1% |
| Future return on equity | -101.5% |
| Analyst coverage | Good |
| Last updated | 31 Jan 2025 |
Recent future growth updates
No updates
Recent updates
Disc Medicine: Potential Promise Amid Uncertainty
Jan 21Disc Medicine, Inc. (NASDAQ:IRON) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 02
Disc Medicine: Achieving Functional Endpoint More Important
Oct 06Disc Medicine (NASDAQ:IRON) Is In A Good Position To Deliver On Growth Plans
Aug 13Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress
Jun 14Disc Medicine: What's Behind The Huge Rally
Jan 31Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 107 | -146 | -152 | -156 | 6 |
| 12/31/2026 | 23 | -178 | -166 | -167 | 7 |
| 12/31/2025 | N/A | -157 | -106 | -144 | 8 |
| 12/31/2024 | N/A | -114 | -91 | -105 | 8 |
| 9/30/2024 | N/A | -103 | -84 | -84 | N/A |
| 6/30/2024 | N/A | -91 | -74 | -74 | N/A |
| 3/31/2024 | N/A | -81 | -72 | -72 | N/A |
| 12/31/2023 | N/A | -76 | -74 | -73 | N/A |
| 9/30/2023 | N/A | -64 | -65 | -65 | N/A |
| 6/30/2023 | N/A | -66 | -68 | -68 | N/A |
| 3/31/2023 | N/A | -60 | -64 | -64 | N/A |
| 12/31/2022 | N/A | -47 | -42 | -42 | N/A |
| 9/30/2022 | N/A | -44 | -39 | -39 | N/A |
| 6/30/2022 | N/A | -37 | -35 | -34 | N/A |
| 3/31/2022 | N/A | -37 | -33 | -33 | N/A |
| 12/31/2021 | N/A | -36 | -28 | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IRON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IRON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IRON is forecast to have no revenue next year.
High Growth Revenue: IRON is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IRON is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 03:18 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Disc Medicine, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Douglas Tsao | H.C. Wainwright & Co. |